Table 2.
Clinical End Points of Atherosclerotic and Nonatherosclerotic Events in Placebo and Cinacalcet Groups
| Event Type | Atherosclerotic Event | Nonatherosclerotic Event | ||||||
|---|---|---|---|---|---|---|---|---|
| Placebo | Cinacalcet | Placebo | Cinacalcet | |||||
| First Event | All Events | First Event | All Events | First Event | All Events | First Event | All Events | |
| Myocardial infarction | 140 (32.0) | 248 (28.5) | 150 (35.1) | 256 (30.0) | — | — | ||
| Nonhemorrhagic stroke | 66 (15.1) | 83 (9.5) | 63 (14.8) | 86 (10.1) | — | — | ||
| Hemorrhagic stroke | — | — | 22 (4.4) | 27 (4.1) | 34 (7.4) | 41 (6.5) | ||
| Heart failure | — | – | 236 (47.5) | 343 (52.4) | 204 (44.3) | 327 (52.1) | ||
| Hospitalization for unstable angina | 54 (12.3) | 76 (8.7) | 39 (9.1) | 64 (7.5) | — | — | ||
| Peripheral vascular event | 171 (39.0) | 454 (52.1) | 164 (38.4) | 424 (49.7) | — | — | ||
| Fatal pulmonary embolism | — | — | 3 (0.6) | 4 (0.6) | 6 (1.3) | 6 (1.0) | ||
| Sudden death | — | — | 157 (31.6) | 182 (27.8) | 143 (31.0) | 166 (26.5) | ||
| Death from cardiovascular procedure | 6 (1.4) | 7 (0.8) | 6 (1.4) | 15 (1.8) | — | — | ||
| Other fatal cardiovascular event | 1 (0.2) | 3 (0.3) | 5 (1.2) | 8 (0.9) | 22 (4.4) | 30 (4.6) | 26 (5.6) | 28 (4.5) |
| Unknown cardiovascular death cause | — | — | 57 (11.5) | 68 (10.4) | 48 (10.4) | 59 (9.4) | ||
| Total, n | 438 | 871 | 427 | 853 | 497 | 654 | 461 | 627 |
Values are n (%). There were no statistically significant differences in the distribution of the component clinical events between the group randomized to placebo and the group randomized to cinacalcet. χ2 P=0.34 and 0.28 for first atherosclerotic and nonatherosclerotic events, respectively; 0.204 and 0.475 for all atherosclerotic and nonatherosclerotic events, respectively (χ2 test).